Matthew Stolz, OD
Optometrist · Clinton, SCNPI 1548690969
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,709 of the $9,545 with a category attached, or 80.8%. 25 manufacturers reported payments, led by Biotissue Holdings Inc. at 28.0% of the total. Reporting peaked in 2024 at $3,864 and has fallen 60.9% since, to $1,509 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $52.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$669
- Bausch & Lomb, A Division Of Bausch Health US, LLC$575
- Dompe US, Inc.$531
- Rxsight Inc$424
- plus $3K from 19 others
What the payments were for
- Travel & lodging$1,66217%
- Food & beverage$7,70981%
- Entertainment$1742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 26 | $2,676 |
| Alcon | 25 | $1,755 |
| Sun Pharmaceutical Industries Inc. | 20 | $669 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $575 |
| Dompe US, Inc. | 15 | $531 |
| Rxsight Inc | 5 | $424 |
| Sight Sciences, Inc. | 12 | $391 |
| Oyster Point Pharma, Inc. | 10 | $372 |
| Coopervision Inc. | 6 | $354 |
| Optos, Inc. | 3 | $271 |
| AbbVie(2 entities) | 8 | $192 |
| LKC Technologies, Inc. | 2 | $191 |
| Amgen(2 entities) | 3 | $164 |
| Tarsus Pharmaceuticals, Inc. | 3 | $151 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| Bausch & Lomb Americas Inc. | 7 | $121 |
| Shire North American Group Inc | 2 | $115 |
| Johnson & Johnson Vision Care, Inc. | 1 | $108 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $93 |
| Novartis | 5 | $71 |
| Harrow Eye, LLC | 3 | $65 |
| Merz Pharmaceuticals, LLC | 3 | $62 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Glaukos Corporation | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$388
- RXSIGHT INJECTOR CARTRIDGE$388
- RXSIGHT INJECTOR HANDPIECE$388
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$388
- LIGHT ADJUSTABLE LENS (LAL)$388
- TOTAL30$362
- CEQUA$341
- Oxervate$245
- PANORAMIC OPHTHALMOSCOPE$228
- OCT OPHTHALMOSCOPE$228
- TYRVAYA$214
- OMNI(R) SURGICAL SYSTEM (US)$154
- Clareon$142
- AcrySof$139
- DAILIES TOTAL1$136
- Precision 1$136
- Prokera$129
- AmnioGraft$129
- SIMBRINZA$125
- Rhopressa$125
How this compares
$9,545 in reported general payments places this provider in the 95th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 105 | $100,533 |
| Cyclosporine | 63 | $21,127 |
| XiidraLifitegrast | 18 | $20,930 |
| LumiganBimatoprost | 45 | $14,596 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $8,862 |
| Prednisolone Acetate | 209 | $6,564 |
| Loteprednol Etabonate | 40 | $5,382 |
| Alphagan PBrimonidine Tartrate | 16 | $4,162 |
| Latanoprost | 414 | $3,386 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $3,315 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,934 |
| Brimonidine Tartrate | 139 | $2,743 |
| Fluorometholone | 26 | $2,427 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,167 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $1,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $192 | $122,226177 claims |
| Bausch & Lomb Americas Inc.Xiidra | $121 | $20,93018 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $575 | $5,38240 claims |
| AlconSimbrinza | $1,755 | $2,16711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Clinton
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
- Scott OliverRock Hill$16K
- Michael CriswellMount Pleasant$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.